/term/total-liabilities/OSTO:SPEC SpectraCure AB (OSTO:SPEC) Total Liabilities
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraCure AB (OSTO:SPEC) » Definitions » Total Liabilities

SpectraCure AB (OSTO:SPEC) Total Liabilities : kr17.42 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is SpectraCure AB Total Liabilities?

SpectraCure AB's Total Liabilities for the quarter that ended in Mar. 2024 was kr17.42 Mil.

SpectraCure AB's quarterly Total Liabilities increased from Sep. 2023 (kr14.53 Mil) to Dec. 2023 (kr14.98 Mil) and increased from Dec. 2023 (kr14.98 Mil) to Mar. 2024 (kr17.42 Mil).

SpectraCure AB's annual Total Liabilities declined from Dec. 2021 (kr14.84 Mil) to Dec. 2022 (kr12.12 Mil) but then increased from Dec. 2022 (kr12.12 Mil) to Dec. 2023 (kr14.98 Mil).


SpectraCure AB Total Liabilities Historical Data

The historical data trend for SpectraCure AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraCure AB Total Liabilities Chart

SpectraCure AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.41 13.32 14.84 12.12 14.98

SpectraCure AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.24 14.97 14.53 14.98 17.42

SpectraCure AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SpectraCure AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.578+(4.397+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=14.98

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=144.834-129.859
=14.98

SpectraCure AB's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.345+(4.069+0.00099999999999856
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=17.42

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=141.288-123.873
=17.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SpectraCure AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of SpectraCure AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


SpectraCure AB (OSTO:SPEC) Business Description

Traded in Other Exchanges
N/A
Address
Magistratsvagen 10, Lund, SWE, 22643
SpectraCure AB develops treatment planning and laser light dose management for cancer treatment. The Company has developed its software IDOSE, and medical laser devices for the treatment.